Difference between revisions of "Rezvilutamide (SHR-3680)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== A nonsteroidal antiandrogen. ==Preliminary data== ===Prostate cancer=== #'''CHART:''' Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chon...") |
|||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Prostate cancer]]=== | ===[[Prostate cancer]]=== | ||
| − | #'''CHART:''' Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022 Sep 5 | + | #'''CHART:''' Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1249-1260. Epub 2022 Sep 5. [https://doi.org/10.1016/s1470-2045(22)00507-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36075260/ PubMed] NCT03520478 |
==Also known as== | ==Also known as== | ||
Revision as of 13:40, 27 January 2023
Mechanism of action
A nonsteroidal antiandrogen.
Preliminary data
Prostate cancer
- CHART: Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1249-1260. Epub 2022 Sep 5. link to original article PubMed NCT03520478
Also known as
- Code name: SHR3680